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Objective: To explore the reasons for worse cancer survival in people with experience ofmental illness, including
differences by cancer type and psychiatric diagnosis.
Method:NewZealand breast and colorectal cancer registrations (2006–2010)were linked to psychiatric hospital-
ization records for adults (18–64 years). Cancer-speciﬁc survival was compared for recent psychiatric service
users and nonusers using Cox regression. The contributions of deprivation, comorbidity and stage at diagnosis
were assessed for those with schizophrenia or bipolar affective disorder (Group A) and others using mental
health services (Group B).
Results:Of 8762 and 4022 peoplewith breast and colorectal cancer respectively, 440 (breast) and190 (colorectal)
had recent contact with psychiatric services. After adjusting for confounding, risk of death from breast cancerwas
increased for Group A [Hazard Ratio (HR) 2.55 (95% conﬁdence interval 1.49–4.35)] and B [HR 1.62 (1.09–2.39)]
and from colorectal cancer for Group A [HR 2.92 (1.75–4.87)]. Later stage at diagnosis contributed to survival
differences for Group A, and comorbidity contributed for both groups. Fully adjusted HR estimates were breast:
Group A 1.65 (0.96–2.84), B 1.41 (0.95–2.09); colorectal: Group A 1.89 (1.12–3.17), B 1.25 (0.89–1.75)].
Conclusions: The high burden of physical disease and delayed cancer diagnosis in those with psychotic disorders
contributes to worse cancer survival in New Zealand psychiatric service users.
© 2015 Elsevier Inc. All rights reserved.1. Background
Experience of mental illness is associated with adverse physical
health outcomes. People with mental illness have higher rates of
many physical illnesses than others in the population and also fare
worse once diagnosed with physical conditions [1–3]. Understanding
the pathways that lead from experience of mental illness to worse out-
comes from physical health conditions is crucial in enabling health ser-
vices to improve outcomes for this group.
Cancer is a leading cause of death in thosewithmental illness in devel-
oped countries [4,5], andwhile cancer incidence rates have generally been
found to be comparable between people with and without a history of
mental illness, cancer mortality is higher [6]. Cancer mortality depends
on cancer incidence and cancer survival. The small number of studies
which have examined the impact of mental illness on cancer survival
has found disparities across cancer types, mental health diagnoses andHealth, University of Otago
242 New Zealand. Tel.: +64-4-
ningham).settings [7–11]. There is some evidence to suggest that these survival dis-
parities may be due to later diagnosis [10] and being less likely to receive
treatment for cancer [11]. However few studies have had the power to in-
vestigate the contribution of speciﬁc factors to cancer survival disparities.
There are a number of possible pathways to apparently worse cancer
survival. The difference in survival may be due to confounding— the age,
sex and ethnicity of those with experience of mental illness may explain
the differences seen in cancer survival. The higher burden of physical ill-
nesses such as diabetes, heart disease and liver disease among those
with mental illness compared to those without may impact on survival
both directly and through ability to tolerate cancer treatments. People
with mental illness may be less likely to access primary care services,
or their mental illness may overshadow their cancer symptoms when
they do, resulting in cancers being diagnosed later with worse prognosis.
Finally, health care quality, or the likelihood of receiving appropriate and
timely treatment once diagnosed, may impact on subsequent survival.
This study uses information from a national mental health service
dataset linked to a national cancer registry to answer two questions:
ﬁrst, what is the relative importance of the different drivers of cancer
survival (particularly stage and comorbid illness) in explaining differ-
ences in survival after diagnosis with common cancers for those with
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psychiatric diagnosis and cancer type?2. Methods
We examined 5-year survival in a cohort of adults diagnosed with
breast or colorectal cancers between 1/1/2006 and 31/12/2010 and
compared those in contact with public psychiatric services in the 5
years prior to cancer diagnosis to those without such a history. Breast
and colorectal cancers were chosen as the two most commonly regis-
tered cancers in New Zealand (aside from prostate cancer) [12].2.1. Participants
Adults, usually resident in New Zealand, who were diagnosed with
incident breast cancer (ICD10 codes: C50x) or colorectal cancer
(ICD10 codes: C18x C19x C20x) between 1/01/2006 and 31/12/2010,
and were aged 18–64 at cancer diagnosis.2.2. Data sources
All data were extracted from collections held by the New Zealand
Ministry of Health, which were linked using the National Health Index
(a unique identifying number that is assigned to all individuals who
use health services in New Zealand) and subsequently anonymised.
Data on cancer diagnosis came from the New Zealand Cancer Registry,
a population-based register of all malignant cancers diagnosed in
New Zealand (except nonmelanoma skin cancers), with mandatory
reporting by laboratories and clinicians. Data on psychiatric service
use came from the Mental Health Information National Collection (1/
1/2001–30/6/2008) and Project for Integration of Mental Health Data
(1/7/2008–31/12/2010) data collections,which record data on all public
inpatient and outpatient mental health service use in those aged under
65. Data on mortality and cause of death were drawn from the New
Zealand Mortality Data Collection, which records all deaths occurring
in New Zealand. Data on comorbid diagnoses were drawn from the
National Minimum Data Set, which records all inpatient public second-
ary care contacts.2.2.1. Exposure
Recent mental illness was deﬁned as mental illness that has been dis-
ruptive enough to lead to contactwith adult secondarymental health ser-
vices (for assessment and/or treatment) in the 5 years prior to cancer
diagnosis. In order to separately investigate the pathways for different
types of mental illness, participants with mental health service use were
divided into those with any diagnosis of schizophrenia, schizoaffective
disorder, bipolar affective disorder, or other nonorganic psychosis
(ICD10 codes: F20, F25, F28, F29, F30, F31) (Group A) and those with
any other recorded psychiatric diagnoses or no psychiatric diagnosis re-
corded (Group B). The remainder of the cohort (with no recorded con-
tact)was treated as the reference group for calculation of hazards ratios.
Contactwith inpatient psychiatric services over the 5 years prior to can-
cer diagnosis was also used as an alternative measure of severity as a
sensitivity analysis.2.2.2. Outcomes
Cancer-speciﬁc survival (where cancer was identiﬁed as the under-
lying cause of death on the death certiﬁcate) was used as the primary
outcome (those dying of noncancer causes were censored at time of
death). All-cause survival was also estimated with mortality for any
cause being treated as the event of interest. Participants who were still
alive at the end of the follow-up period were treated as censored in
both analyses.2.3. Variables
Age at cancer diagnosiswas calculated fromdate of diagnosis and date
of birth. Agewasmodeled in the survival analyses using a restricted cubic
spline function with three knots (knots at 10th, 50th and 90th percen-
tiles). Sex was used as recorded on the Cancer Registry (male or female),
and this informationwas complete for all of those identiﬁed in the cohort.
Ethnic group, as recorded on the Cancer Registry, was used. There
are fourmain ethnic groups in New Zealand: the indigenousMaori pop-
ulation (14%) and European (70%), Paciﬁc (7%) and Asian (11%) groups
[13]. Multiple ethnic identities can be recorded on the Cancer Registry,
but for reporting, a single prioritized group is used, with the prioritiza-
tion order of Maori, then Paciﬁc, then Asian and then a residual group.
For the analyses reported here, the indigenous Maori population was
compared with all other (non-Maori) groups. Those with missing
ethnicity information were included in the non-Maori group. Further
analysis by ethnic group was limited by small numbers.
Level of deprivation was measured using the NZDep (2006) index,
which is a small area measure of deprivation based on data from the
2006 Census [14]. Deprivation level was missing where information on
area of residence at the time of cancer diagnosis was not available
(about 2%), and these data were imputed using values from multiple
other variables [age, sex (for colorectal cancer), ethnicity, cancer stage, co-
morbidity score andwhether the persondied] to predict likely deprivation
score. The Proc MI (multiple imputation) procedure was used in the
analytic programme SAS, and ﬁve output datasets were created. Depriva-
tion quintiles were used in survival analysis.
The C3 comorbidity index [15]was used to estimate level of comorbid
illness present at the time of cancer diagnosis. This index, speciﬁcally de-
veloped to measure comorbidity in the context of cancer using adminis-
trative hospitalization data, includes up to 42 conditions. For the C3
index, conditions are identiﬁed from ICD-10 coded diagnoses recorded
for any hospitalization event for a given patient in the 5 years prior to
cancer diagnosis. Each condition is weighted according to its impact on
a 1-year noncancer mortality (as a mark of severity). The weights are
summed to give an overall index score for each patient, with a higher
score indicating a higher level of comorbidity. The index was adapted
for the current study to exclude psychiatric diagnoses. Comorbidity was
modeled using a restricted cubic spline function using three knots for
the survival analysis (for breast cancer knots at 0, 0.5 and 1.3; for colorec-
tal cancer knots at 0, 0.5 and 2.0) [16]. For the descriptive analysis C3
scores were divided into three categories: 0, 1–2 and 3+.
Stage at diagnosis is recorded on the Cancer Registry based on all
available information on staging within 3 months of diagnosis. The
SEER (Surveillance Epidemiology and End Results Programme) summary
staging system is used, and this was converted into local, regional and
distant disease for analyses. Those with missing stage data were treated
as having unstaged disease, and this was used as a stage category.
2.4. Analysis
Breast and colorectal cancer cohorts with a history of recent mental
health service use (in the 5 years prior to cancer diagnosis) were com-
pared to those without such a history in terms of demographics, cancer
characteristics and comorbidity. KaplanMeir survival curves for cancer-
speciﬁc mortality were estimated for those with and without a history
of mental health service use and visually compared to assess propor-
tionality of hazards. Cox proportional hazards modeling was used to
compare cancer-speciﬁc and all-cause survival between those with re-
cent mental health service use and those without and to investigate
the contribution of demographic confounders (age, sex, ethnicity) and
factors likely to be on the causal pathway (deprivation, comorbidity
and stage at diagnosis). Survival estimates were also produced using
the Fine Gray method which takes into account deaths from competing
causes [17] to check for any bias due to analysis method selection. A di-
rected acyclic graph (DAG) was used to plot the assumed causal
Fig. 1. DAG, demonstrating assumed causal and confounding relationships.
Table 1
Breast cancer cohort (n=8772) description of sociodemographic and clinical characteris-
tics by mental health service use groups.
Factor/Characteristic Group A
People with a
diagnosis of
functional
psychosis
Group B
People in
contact with
mental health
services for
other reasons
No MHS use
n % n % n %
Total number 112 328 8322
Age at diagnosis
18–44 21 18.75 99 30.18 1746 20.98
45–54 48 42.86 139 42.38 3367 40.46
55–64 43 38.39 90 27.44 3209 38.56
Gender
Female 112 100.0 328 100.0 8322 100.0
Ethnicity
NZ Maori 31 27.7 67 20.4 1194 14.3
Non-Maori 81 72.3 261 79.6 7128 85.7
NZDep quintile
1 10 8.9 48 14.6 1677 20.2
2 11 9.8 47 14.3 1511 18.2
3 17 15.2 67 20.4 1592 19.1
4 34 30.4 78 23.8 1699 20.4
5 37 33.0 83 25.3 1624 19.5
Missing 3 2.7 5 1.5 219 2.6
Comorbidity score
0 64 57.1 231 70.4 7382 88.7
1–2 38 33.9 67 20.4 775 9.3
3+ 10 8.9 30 9.1 165 2.0
Stage
Local 53 47.3 162 49.4 4467 53.7
Regional 38 33.9 123 37.5 3021 36.3
Distant 11 9.8 16 4.9 277 3.3
Unstaged 10 8.9 27 8.2 557 6.7
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follow-up time for the survival analysis was 5 years.
All analysis was performed using SAS version 9.3.
Ethical approval for this study was granted by the New Zealand
Multi-region Ethics Committee (reference number MEC/12/05/046).
3. Results
We identiﬁed 8762 women with a diagnosis of breast cancer, of
whom 440 had had contact with mental health services in the 5 years
prior to cancer diagnosis [112 had a diagnosis of schizophrenia,
schizoaffective disorder or bipolar disorder (Group A)]. There were
4022 people identiﬁed with colorectal cancer diagnosed before age 65,
of whom 190 had contact with psychiatric services in the 5 years prior
(33 in Group A). For both cancers, compared to people without any re-
centmental health service use, those with a history of recentmental ill-
ness (both Group A and Group B) were more likely to be of indigenous
(Maori) ethnicity, live in deprived areas and have a higher level of phys-
ical comorbidity. These patterns were most marked for mental health
service users in Group A. People in Group A also had a less favorable dis-
tribution of stage at diagnosis (Tables 1 and 2) for both cancer cohorts.
Women with breast cancer and a history of mental health service
use (both Groups A and B)weremore likely to die from their breast can-
cer compared to other women (Fig. 2). Women in Group A had two and
half times the risk of death after adjusting for confounding by age and
ethnicity [adj. HR 2.55 (95% CI 1.49–4.35)], while women in Group B
had a 60% increased risk of death [adj. HR 1.62 (1.09–2.39)] (Table 3).
The factors contributing to poor survival were different for these two
groups, as shown in Table 3. After adjusting for age and ethnicity,
stage accounted for 45% of the remaining survival difference for Group
Abut didnot account for anyof the survival difference forGroupB. Comor-
bidity accounted for 25–30% of the remaining difference after adjusting for
stage and deprivation for both Group A and Group B. After adjustment for
all available factors, a substantial survival difference remained and was
similar in magnitude for Group A (fully adj. HR 1.65 (0.96–2.84) and
Group B (fully adj. HR 1.41 (0.95–2.09). The results were not substantially
different when all-cause survival was used as an outcome measure.
A similar picture was seen for colorectal cancer survival, although
the differences between the diagnostic groups were more marked
(Table 4) (Fig. 3). Those in Group A were nearly three times as likely
to die from their cancer after adjusting for demographic confounders
[HR 2.92 (95% CI 1.75–4.87)], while those in group B did not have a sig-
niﬁcantly elevated risk of death [HR 1.15 (0.84–1.59)]. As for breast can-
cer, stagewas an important contributor to survival differences for GroupA. After adjusting for age and ethnicity, stage accounted for 39% of the
remaining survival difference for Group A but did not account for the
survival difference for Group B. After adjusting for stage and depriva-
tion, comorbidity accounted for 10% of the remaining difference for
Group A and around 50% of the remaining difference for Group B. Full
adjustment for stage, deprivation and comorbidity reduced the estimate
for Group A [HR 1.89 (1.12–3.17)], while adjustment for these factors
increased the estimate for Group B [HR 1.25 (0.89–1.75)]. Aswith breast
cancer, similar results were found for all-cause survival.
Using competing cause methods instead of Cox regression methods
did not alter the estimates (changes to hazard ratios at the second
Table 2
Colorectal cancer cohort (n=4022) description of sociodemographic and clinical charac-
teristics by mental health service use groups.
Factor/Characteristic Group A
People with a
diagnosis of
functional
psychosis
Group B
People in
contact with
mental health
services for
other reasons
No MHS use
n % n % n %
Total number 33 157 3832
Age at diagnosis
18–44 4 12.1 38 24.2 454 11.8
45–54 13 39.4 38 24.2 999 26.1
55–64 16 48.5 81 51.6 2379 62.1
Gender
Female 17 51.5 77 49.0 1761 46.0
Male 16 48.5 80 51.0 2071 54.0
Ethnicity
NZ Maori 3 9.1 28 17.8 326 8.5
Non-Maori 30 90.9 129 82.2 3506 91.5
NZDep quintile
1 3 9.1 17 10.8 754 19.7
2 5 15.2 28 17.8 658 17.2
3 1 3.0 29 18.5 789 20.6
4 9 27.3 50 31.8 824 21.5
5 15 45.5 32 20.4 697 18.2
Missing 0 0.0 1 0.6 110 2.9
Comorbidity score
0 15 45.5 85 54.1 2922 76.3
1–2 13 39.4 45 28.7 743 19.4
3+ 5 15.2 27 17.2 167 4.4
Stage
Local 4 12.1 45 28.7 883 23.0
Regional 13 39.4 48 30.6 1501 39.2
Distant 13 39.4 39 24.8 835 21.8
Unstaged 3 9.1 25 15.9 613 16.0
Table 3
Hazard ratio estimates (fromCox regressionmodels) for breast cancermortality according
to mental health service use history, unadjusted and adjusted for confounders/mediators.
Group A Group B
Model⁎ HR 95% CI HR 95% CI
0 2.62 1.54–4.46 1.72 1.17–2.54
1 2.55 1.49–4.35 1.62 1.09–2.39
2 1.85 1.08–3.17 1.63 1.10–2.41
3 1.81 1.05–3.11 1.60 1.08–2.36
4 1.65 0.96–2.84 1.41 0.95–2.09
⁎ 0=crude survival; 1=adj for age+ethnicity; 2=1+SEER stage at diagnosis;
3=2+NZ Deprivation Index score; 4=3+C3 comorbidity index score.
504 R. Cunningham et al. / General Hospital Psychiatry 37 (2015) 501–506decimal place only— results not shown). Using inpatient versus outpa-
tient service use as an alternative measure of severity of psychiatric ill-
ness (instead of the grouping by psychiatric diagnosis reported above)
gave similar results, with those with a history of inpatient service use
having signiﬁcantly worse survival than thosewho had used outpatient
services only (results not shown).
4. Discussion
Men and women with a history of recent psychiatric service use in
New Zealand had poorer survival after diagnosis with breast or colorectal
cancer than those who did not have such a history. Those who had been
diagnosedwith schizophrenia, schizoaffective disorder or bipolar disorder
prior to cancer diagnosis had two and half times (breast) to three timesFig. 2. Breast cancer survival (unadjusted Kaplan–Meier estimates of cancer-speciﬁc sur-
vival) by mental health service (MHS) use history [Group A (psychosis diagnosis)
n=112, Group B (other MHS use) n=328 and no history of service use n=8322].(colorectal cancer) the risk of dying from their cancer within 5 years,
after adjusting for confounding. Late stage at diagnosis explained more
than a third of the survival difference for this group, but was not a factor
for service userswith other diagnoses. Comorbid illness also played an im-
portant role in explaining survival disparities for both groups. After adjust-
ment for available factors, a 30 to 80% survival disadvantage remained
unexplained, although this was no longer signiﬁcant except in the case
of colorectal cancer in people with schizophrenia or bipolar disorder. A
similar pattern was seen for both breast and colorectal cancers.
The ﬁnding of worse cancer survival associated with a history of
mental illness is consistent with the small number of other studies
that have examined this question, both for speciﬁc cancers ormental ill-
nesses [11,18], and for cancers or mental disorders combined [7,8]. It is
also consistent with the wider literature suggesting that cancer mortal-
ity is disproportionately increased compared to incidence in people
with a history of mental illness [6,19]. The factors potentially contribut-
ing to cancer survival inequalities include clinical factors such as comor-
bidity and health service factors including access to screening and early
diagnosis and access to timely treatment. In this study we were able to
investigate the impact of stage at diagnosis and comorbidity.
Other studies which have examined the role of cancer stage at diag-
nosis in survival disparities for people with history of mental illness
have produced conﬂictingﬁndings,with some studiesﬁnding thatmen-
tal illnesses are associated with late diagnosis [10], while others ﬁnding
an association with early diagnosis [20], or no association [7].
Preexisting illness (including mental illness) can inﬂuence the stage at
which cancers are diagnosed in a variety of ways, sometimes
overshadowing cancer symptoms resulting in late diagnosis, but in
other cases leading to increased surveillance resulting in earlier cancer
diagnosis, depending on factors such as the severity of the illness, the
type of cancer and the health system context [21]. For example, more
severe illness may distract attention from cancer symptoms resulting
in late diagnosis (as may have occurred with schizophrenia and bipolar
disorder in this study), while less severe illness may result in earlier di-
agnosis through increased contact with the health system and hence in-
creased opportunities for detection.Where all cancers and/or all mental
illnesses are examined together, the different stage distribution for dif-
ferent cancers andmental illnessesmay be obscured, resulting in no ap-
parent relationship (for example [7]). Differences in ﬁndings for the
same mental illness diagnosis (e.g., schizophrenia) are likely to relateTable 4
Hazard ratio estimates (from Cox regression models) for colorectal cancer mortality accord-
ing tomental health service use history, unadjusted and adjusted for confounders/mediators.
Group A Group B
Model⁎ HR 95% CI HR 95% CI
0 2.84 1.70–4.73 1.21 0.88–1.67
1 2.92 1.75–4.87 1.15 0.84–1.59
2 2.17 1.30–3.63 1.47 1.07–2.04
3 2.01 1.20–3.36 1.47 1.06–2.03
4 1.89 1.12–3.17 1.25 0.89–1.75
⁎ 0=crude survival; 1=adj for age+sex+ethnicity; 2=1+SEER stage at diagnosis;
3=2+NZ Deprivation Index score; 4=3+C3 Comorbidity Index score.
Fig. 3. Colorectal cancer survival (unadjusted Kaplan–Meier estimates of cancer-speciﬁc
survival) by mental health service use history (Group A (psychosis diagnosis) n=33,
Group B (other MHS use) n=157 and no history of service use n=3832).
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earlier lung cancer diagnosis in Medicare patients with schizophrenia
than others [20] suggests that these patients undergo a high degree
of surveillance of the type likely to pick up lung cancer (likely chest
x-rays) in the Medicare system.
Late diagnosis of breast cancers in people with schizophrenia and
bipolar disorder in New Zealandmay relate to poorer access to screening
for breast cancer. In New Zealand, free population-based screening is of-
fered for breast cancer, and coverage rates across the population are
high but vary by ethnicity [22]. Screening coverage for people with expe-
rience of mental illness in New Zealand is not known, but most studies in
other countries have found lower screening coverage rates in peoplewith
severe mental illness [23]. Population-based screening for colorectal can-
cerwas not offered at the time of this study. Access to primary care is also
important for early cancer diagnosis. TheNewZealand health systempro-
vides public secondary and tertiary care, including cancer and mental
health care, free of charge. However primary care is provided by private
practitioners (although largely publicly funded), and copayments are
charged for primary care visits and prescriptions. These copayments
have been signiﬁcantly reduced in recent years but continue to present
a barrier to access for some groups [24]. In addition to cost barriers,
other factors such as overshadowing of physical by psychiatric symptoms
and confusion among providers about responsibility for the physical
health care of people with severe mental illness may contribute to delays
in diagnosis. However as the large linkage studies of cancer survival dis-
parities inDenmarkhave shown, ready access to primary care and screen-
ing for early detection, as is provided by theDanish health system, is not a
solution by itself to survival disparities associated with deprivation or di-
agnoses such as schizophrenia [25].
Coexisting illness (referred to as comorbidity) is also known to be an
important factor in cancer survival disparities [26]. Comorbidity can im-
pact on cancer stage at diagnosis as explained above, but independently
can also impact on survival through inﬂuencing treatment options, and
the survivability of treatments and the cancer itself.Most studies of can-
cer survival in the context of mental illness have either had no informa-
tion on comorbidity (e.g., [7]), treated comorbidity as a confounder
(e.g., [8]) or included it inmodels together with stage so that its individ-
ual contribution could not be assessed (e.g., [27]). Examining the impact
of comorbid illness on survival as amediator draws attention to the fact
that the impact of mental illness cannot be considered in isolation —
those with mental illness are often also living with physical illness,
and cancer treatment needs to be considered in this complex context.
In this studywe found that comorbidity, after accounting for stage at di-
agnosis, is an important factor in understanding survival disparities,
particularly for those using mental health services for reasons other
than psychotic illnesses. Moreover, the impact of comorbidity on treat-
ment decisions is not inevitable, and in fact there is evidence that treat-
ment may at times be inappropriately withheld on the basis ofcomorbid illness [28,29]. Therefore comorbidity should be considered
a cause of mental health-related survival differences that is potentially
amenable to intervention.
Beyond the effect of individual factors and timely diagnosis, receipt
of timely cancer treatment has also been shown to play an important
role in cancer survival disparities, and this is likely to also be the case
for people with mental illness [30]. Several studies have found that
those with a history of mental illness are less likely to receive treat-
ments such as surgery and chemotherapy [8,27,11]. Moreover, the stig-
ma and discrimination associated with mental illness is likely to be
playing a role in these treatment disparities [31,32]. It was not possible
to ascertain complete information on treatment receipt in this study.
However after adjustment for all available factors, those using mental
health services hadworse survival than those without a history of men-
tal health service use (although the differences were for the most part
no longer statistically signiﬁcant), and some of this remaining unex-
plained survival disadvantage may relate to differences in treatment.
While secondary care, including mental health and cancer care, is uni-
versally available free of charge in New Zealand's public system, evi-
dence of differences in treatment receipt by ethnicity [33], as well as
reports of experience of discrimination by health services from people
with experience of mental illness [31], suggests that treatment receipt
may be a factor in the survival differences found.
4.1. Strengths and weaknesses
This is a population-based study, using complete national data,
which allowed longitudinal observation of all New Zealanders using
mental health services who subsequently developed common cancers,
and comparison to all other New Zealanders with these cancers. This
study focused on those under 65, as data on mental health service use
for those over 65 are not uniformly or universally collected in New
Zealand. Many of the other studies on this topic have been limited to
the US Medicare population (over 65). The younger group reported on
in the current study is more amenable to interventions to improve can-
cer survival, and furthermore prevention of premature cancer mortality
is an important policy goal, so investigation of this group provides im-
portant information for health services and policy makers. It is likely
that there was little loss to follow up, as all deaths occurring in New
Zealand were captured. It was possible to separately examine breast
and colorectal cancer outcomes and the pathways leading to them for
people with a diagnosis of schizophrenia, bipolar disorder or
schizoaffective disorder, and all others in contact with mental health
services, with sufﬁcient power to investigate differences. Therewas rea-
sonable completeness of data, including cancer stage. Multiple imputa-
tion was performed to augment deprivation status completeness.
There was limited information available on psychiatric diagnosis
(around 50% had no diagnosis recorded or had “no diagnosis” recorded
on their record), so it was not possible to investigate differences in can-
cer survival and pathways between types of mental illness in more de-
tail. However, it was possible to identify those with schizophrenia and
bipolar disorder, conditions generally regarded as themost severemen-
tal illnesses, and it is likely that peoplewith these diagnoseswould have
this information correctly recorded. Itwas not possible to obtain reliable
information on cancer treatment for this study, and it is likely that treat-
ment differences would explain some of the remaining survival differ-
ences. Data on lifestyle factors such as smoking status were not
available, but their potential impacts on cancer survival are likely to be
at least partially accounted for by including a measure of comorbidity.
There is some imprecision in the measurement of each pathway exam-
ined. Stage at diagnosis is based on Cancer Registry records, and it is
possible that thequality of stagingdatamight vary bymental health sta-
tus. For example if thosewithmental illnesswere less thoroughly inves-
tigated, then the Cancer Registry records might incorrectly report
disease at a lower stage, resulting in an underestimation of the differ-
ence between those with and without mental illness. Comorbidity
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from previous diagnoses recorded on hospital records, using an index
that predicts the relationship between these diagnoses and mortality
risk [15]. Not all preexisting illness will be diagnosed, and not all diag-
nosed illnesseswill necessarily be recorded on hospitalmedical records,
and there could be a bias in either direction for those using mental
health services (i.e., diagnoses may be more or less likely to be made
and more or less likely to be recorded, and this would be likely to vary
by the severity and type of mental illness). The comorbidity index
used here which is designed speciﬁcally for use in cancer populations
explains a larger proportion of the difference in survival than the com-
monly used Charlson comorbidity index, and it is possible that a better
measure of comorbidity (if that were possible) would explain even
more of the survival difference.
4.2. Implications
These ﬁndings add to the limited body of research examining cancer
survival in adults with experience of mental illness. Consistent with
other work, we have found worse breast and colorectal cancer survival
in this group, and in particular much worse survival among those diag-
nosed with schizophrenia or bipolar disorder. Comorbidity is a contrib-
utor to the survival differences found for all those using mental health
services, while late stage at diagnosis is an important contributor for
those with themost severe psychiatric illnesses. Ensuring timely cancer
diagnosis for those with schizophrenia and bipolar disorder is therefore
important in improving survival, but on its ownwill not be enough. Pre-
ventive and treatment interventions to reduce the physical disease bur-
den in thosewithmental illness and treatment guidelines to ensure that
comorbid illness does not unnecessarily impede cancer treatment also
have the potential to improve cancer survival. The gap in outcomes
that remains unexplained may be partly due to imprecision in measur-
ing other factors. However it is also likely that timely access to appropri-
ate treatment and less tangible factors on the treatment pathway such
as communication and the relationships between clinicians and patients
play an important role in cancer outcomes for thosewithmental illness.
Further investigation of the cancer treatment journey for those with ex-
perience of mental illness is needed to understand the reasons for the
remaining unexplained gap in outcomes.
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